Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?

To: CO who wrote (526)	3/9/1998 11:27:00 PM
From: Brad	Read Replies (1) \| Respond to of 4650

To ALL: I have some very interesting findings here regarding the ADOT/BIOMODA Lung Cancer Research (Early Detection & Treatment)... Here's part of an article from a lung cancer report (Spring 1996). It is interesting in that it refers to Dr Geno Saccomanno as "the world's best pulmonary cyto-pathologist." Dr Saccomanno is also part of the Scientific Advisory Board of BIOMODA. biomoda.com Here's the site for the article followed by the part of the article that talks about Dr Saccomanno and the fluorescence imaging process known as "LIFE"... emphysemafoundation.org ---------------------------------------------------- Early detection of lung cancer Sputum cytology is an important method for detecting lung cancer in its early stages. Unfortunately, not all medical centers have highly trained ctyo-pathologists and technicians that can read sputum slides. New technology might soon change that. The Oncometrics Company (a subsidiary of XILLIX) of Vancouver, British Columbia, has a new imaging computer that is programmed to identify lung cancer cells on properly prepared slides of expectorated sputum. This could make sputum cytology a practical method for testing all patients who smoke at any medical center. In a prospective study now under way, the computer system is being compared to the world's best pulmonary cyto-pathologist, Dr. Geno Saccomanno, and to cyto-pathologists in four study centers. Centers participating in this study are located in Colorado; Vancouver; Tokyo; and Bochum, Germany. If the unit is successful in identifying lung cancer cells, the study will move into its next phase. When patients produce a sputum sample that proves to contain lung cancer or high dysplasia (abnormalities), they are candidates for bronchoscopy. In this study, most of the bronchoscopy will be done with the new lung imaging, fluorescence endoscope (LIFE). The LIFE bronchoscope is better at finding early lung cancers than the white light bronchoscopes (Lam S. et al: J Thorac Cardiovasc Surg 1993; 105:1035-1045. ----------------- End of Section ---------------------- NOTE: This article came out in the Spring 1996. Now, 2 years later, I believe they are preparing to do commercial screening. ADOT could be positioned for huge profits from this. Exciting stuff!! Best wishes, Brad